Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing.

Autor: Triner D; Department of Urology, Michigan Medicine, Ann Arbor, USA., Graf RP; Foundation Medicine, Cambridge, USA., Madison RW; Foundation Medicine, Cambridge, USA., Gjoerup O; Foundation Medicine, Cambridge, USA., Tukachinsky H; Foundation Medicine, Cambridge, USA., Ross JS; Foundation Medicine, Cambridge, USA; Department of Pathology, Upstate Medical University, Syracuse, USA; Department of Urology, Upstate Medical University, Syracuse, USA; Department of Medicine (Oncology), Upstate Medical University, Syracuse, USA., Quintanilha JCF; Foundation Medicine, Cambridge, USA., Li G; Foundation Medicine, Cambridge, USA., Cheng HH; University of Washington, Fred Hutchinson Cancer Center, Seattle, USA., Pritchard CC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, USA., Zurita AJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Qin Q; Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, USA., Zhang T; Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, USA., Agarwal N; Department of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA., Reichert ZR; Department of Hematology/Oncology, University of Michigan, Ann Arbor, USA., Mateo J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Barcelona Hospital Campus, Barcelona, Spain., Cieslik M; Department of Pathology, University of Michigan, Ann Arbor, USA., Morgan TM; Department of Urology, Michigan Medicine, Ann Arbor, USA. Electronic address: tomorgan@med.umich.edu.

Publikováno v: ESMO open [ESMO Open] 2024 Sep; Vol. 9 (9), pp. 103684. Date of Electronic Publication: 2024 Sep 09.

Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.

Autor: Rotow JK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lee JK; Department of Clinical Development, Foundation Medicine, Inc., Boston, Massachusetts., Madison RW; Department of Clinical Development, Foundation Medicine, Inc., Boston, Massachusetts., Oxnard GR; Department of Clinical Development, Foundation Medicine, Inc., Boston, Massachusetts., Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schrock AB; Department of Clinical Development, Foundation Medicine, Inc., Boston, Massachusetts. Electronic address: aschrock@foundationmedicine.com.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Feb; Vol. 19 (2), pp. 227-239. Date of Electronic Publication: 2023 Oct 06.

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.

Autor: Pellini B; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.; Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida., Madison RW; Foundation Medicine, Inc., Cambridge, Massachusetts., Childress MA; Foundation Medicine, Inc., Cambridge, Massachusetts., Miller ST; Foundation Medicine, Inc., Cambridge, Massachusetts., Gjoerup O; Foundation Medicine, Inc., Cambridge, Massachusetts., Cheng J; Genentech, Inc., South San Francisco, California., Huang RSP; Foundation Medicine, Inc., Cambridge, Massachusetts., Krainock M; Natera, Inc., San Carlos, California., Gupta P; Genentech, Inc., South San Francisco, California., Zou W; Genentech, Inc., South San Francisco, California., Shames DS; Genentech, Inc., South San Francisco, California., Moshkevich S; Natera, Inc., San Carlos, California., Ballinger M; Genentech, Inc., South San Francisco, California., Liu MC; Natera, Inc., San Carlos, California., Young A; Foundation Medicine, Inc., Cambridge, Massachusetts., Srivastava MK; Genentech, Inc., South San Francisco, California., Oxnard GR; Foundation Medicine, Inc., Cambridge, Massachusetts., Socinski MA; AdventHealth Cancer Institute, Orlando, Florida.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 14; Vol. 29 (22), pp. 4596-4605.

Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.

Autor: Powles T; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London ECMC, Barts Health, London, United Kingdom., Young A; Foundation Medicine, Cambridge, MA, United States., Nimeiri H; Foundation Medicine, Cambridge, MA, United States., Madison RW; Foundation Medicine, Cambridge, MA, United States., Fine A; Foundation Medicine, Cambridge, MA, United States., Zollinger DR; Foundation Medicine, Cambridge, MA, United States., Huang Y; Foundation Medicine, Cambridge, MA, United States., Xu C; Foundation Medicine, Cambridge, MA, United States., Gjoerup OV; Foundation Medicine, Cambridge, MA, United States., Aushev VN; Natera, Austin, TX, United States., Wu HT; Natera, Austin, TX, United States., Aleshin A; Natera, Austin, TX, United States., Carter C; Roche/Genentech, South San Francisco, CA, United States., Davarpanah N; Roche/Genentech, South San Francisco, CA, United States., Degaonkar V; Roche/Genentech, South San Francisco, CA, United States., Gupta P; Roche/Genentech, South San Francisco, CA, United States., Mariathasan S; Roche/Genentech, South San Francisco, CA, United States., Schleifman E; Roche/Genentech, South San Francisco, CA, United States., Assaf ZJ; Roche/Genentech, South San Francisco, CA, United States., Oxnard G; Foundation Medicine, Cambridge, MA, United States., Hegde PS; Foundation Medicine, Cambridge, MA, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Jul 31; Vol. 13, pp. 1221718. Date of Electronic Publication: 2023 Jul 31 (Print Publication: 2023).

Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab.

Autor: Kansara M; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; Faculty of Medicine, St. Vincent's Clinical School, UNSW Sydney, Kensington, NSW, Australia., Bhardwaj N; Foundation Medicine, Inc., Cambridge, MA, USA., Thavaneswaran S; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; Faculty of Medicine, St. Vincent's Clinical School, UNSW Sydney, Kensington, NSW, Australia.; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, NSW, Australia., Xu C; Foundation Medicine, Inc., Cambridge, MA, USA., Lee JK; Foundation Medicine, Inc., Cambridge, MA, USA., Chang LB; Foundation Medicine, Inc., Cambridge, MA, USA., Madison RW; Foundation Medicine, Inc., Cambridge, MA, USA., Lin F; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; Faculty of Medicine, St. Vincent's Clinical School, UNSW Sydney, Kensington, NSW, Australia.; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, NSW, Australia., Hsu E; Radiology Department, St Vincent's Hospital, Sydney, NSW, Australia., Patel VK; Natera, Austin, TX, USA., Aleshin A; Natera, Austin, TX, USA., Oxnard GR; Foundation Medicine, Inc., Cambridge, MA, USA., Simes J; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, NSW, Australia., Nimeiri H; Foundation Medicine, Inc., Cambridge, MA, USA., Thomas DM; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; Faculty of Medicine, St. Vincent's Clinical School, UNSW Sydney, Kensington, NSW, Australia.

Publikováno v: Molecular oncology [Mol Oncol] 2023 Feb; Vol. 17 (2), pp. 298-311. Date of Electronic Publication: 2022 Dec 13.